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Abstract Diabetes is a complex disease characterized
by chronic hyperglycemia and multiple phenotypes. In
1995, we used a doctor-nurse-clerk team and structured
protocol to establish the Hong Kong Diabetes Registry
in a quality improvement program. By 2009, we had
accrued 2616 clinical events in 9588 Chinese type 2
diabetic patients with a follow-up duration of 6 years.
The detailed phenotypes at enrollment and follow-up
medications have allowed us to develop a series of risk
equations to predict multiple endpoints with high
sensitivity and specificity. In this prospective database,
we were able to validate findings from clinical trials in
real practice, confirm close links between cardiovascular
and renal disease, and demonstrate the emerging
importance of cancer as a leading cause of death. In
addition to serving as a tool for risk stratification and
quality assurance, ongoing data analysis of the registry
also reveals secular changes in disease patterns and
identifies unmet needs.
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Introduction
Diabetes has become a global epidemic in both
developing and developed areas. In 2007, the Interna-
tional Diabetes Federation predicted that 170 million
people would be diabetic and that 60% of those affected
would be from Asia. However, national figures from
China in 2007 and 2008 indicated that 97 million
people had diabetes and 150 million people had pre-
diabetes in China alone [1]. In May 2010, the United
Nations passed a resolution in recognition of the burden
of chronic diseases, including diabetes, heart disease,
cancer and respiratory disease, on individuals, family,
and society. Collectively, these chronic diseases explain
60% of global deaths, requiring urgent multi-sectorial
efforts to combat these health threats [2].
In the past two decades, cohort studies, randomized
controlled trials, and meta-analyses have confirmed the
predictive values of many risk factors and the benefits of
their modification on clinical outcomes. Yet, national and
international surveys have persistently shown marked
chasms between guidelines and practice. In the International
Diabetes Mellitus Practice Survey (IDMPS), which enrolled
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more than 10,000 diabetic patients from countries outside the
United States and Europe, over 30% of patients had never
been assessed for complications and risk factor control, only
20% to 30% were achieving recommended treatment goals
(blood pressure [BP] <130/80 mm Hg, low-density lipopro-
tein cholesterol [LDL-C] < 2.6 mmol/L, and glycated
hemoglobin [HbA1c] < 7%), and less than 5% were
achieving all three goals. The suboptimal adherence to
recommended clinical procedures to detect risk factors and
complications and low rates in attaining treatment goals were
similar irrespective of health care settings (private vs public)
and the experience of health care professionals (specialists vs
general internists) [3•].
Phenotypic Heterogeneity of Diabetes
and its Co-Morbidities
Diabetes has many phenotypes due to complex interactions in
genetic, epigenetic, perinatal, lifestyle, socioeconomic, and
environmental factors that influence neurohormonal, meta-
bolic, and cell signaling pathways. Apart from hyperglycemia
due to varying degrees of insulin deficiency and resistance,
these metabolic changes are often accompanied by risk factors
such as obesity, hypertension, dyslipidemia, and inflamma-
tion. The result is widespread vascular and nerve damage.
These diabetic phenotypes interact with external factors,
including pharmacologic and non-pharmacologic interven-
tions, in a non-linear and multiplicative manner to modify the
clinical course with different presentations and outcomes.
Challenges in Delivery of Diabetes Care
Most national and international guidelines recommend
comprehensive assessment for risk factors and compli-
cations in all diabetic patients at diagnosis and then at
regular intervals thereafter. These procedures are impor-
tant given the silent, progressive, but highly preventable
nature of diabetic complications. However, without
changing the logistics of health care delivery at the
level of the clinic, it is often challenging or even
impossible for a busy doctor with an average consulta-
tion time of 5 to 20 min to perform these assessments
and manage the large amount of clinical information to
make informed individualized decisions. Furthermore,
patients with diabetes need to be educated about their
unique risk profiles, and receive education, empower-
ment, and encouragement in order to enhance their self
care and as well as achieve optimal adherence to
treatment regimens. To achieve these cognitive, psycho-
logical, and behavioral changes, rapport between
patients and the health care team is essential.
Using a Trio Team to Establish the Hong Kong Diabetes
Registry
In 1995, motivated by the International Diabetes Federation
St. Vincent’s Declaration, which advocated the use of a
protocol to benchmark quality of care in diabetes and to
simultaneously promote patients’ awareness of rights and
roles [4], we introduced a series of changes to improve the
delivery of diabetes service at the Prince of Wales Hospital,
Hong Kong (Fig. 1).
1. We empowered our diabetes nurses to perform compli-
cation assessment using a protocol for independent
collection of information in a structured manner, which
allows doctors to maximize efficiency in decision
making during routine visits.
2. We introduced a twice-weekly 4-h session led by one or
two nurses supported by a health care assistant where
8 to 12 diabetic patients were given appointments. All
patients were given instructions on the nature, purpose,
and procedures of the comprehensive assessments,
including attendance after 8 h of fasting.
3. We used structured assessment forms to enable doctors
to provide medical and drug history upon referral,
whereas nurses obtained personal and family history
and activities of self care, followed by clinical measure-
ments and phlebotomy.
4. We trained our nurses to use validated instruments to
examine the feet (eg, graduated tuning fork, monofilament,
Doppler scan) and eye (eg, fundus camera and Snellen’s
chart). In the absence of the latter instruments, a trained
doctor would examine the fundus through dilated pupils
using ophthalmoscope, which took less than 30 min for 10
to 12 patients. Before the patient left, he/she would provide
a random or timed urinary collection for measurement of
urinary albumin-creatinine ratio. All patients were asked to
give written informed consent for data analysis for the
purpose of conducting clinical research.
5. We designed a database with built in definitions for risk
factors, complications and treatment goals, initially
using Microsoft’s dBASE (Redmond, WA) and later
Microsoft Access, for data management and reporting.
A dedicated clerical officer was responsible for data
entry and management of the database.
6. On a weekly basis, a senior endocrinologist reviewed, on
average 20 to 25 reports and recommended action plans to
the referring doctor/team, including addition of insulin,
renin angiotensin system (RAS) blockers, statins to
intensify risk factor control, referral to educators or
proposal of discharge, and follow up plan.
7. We arranged the same group of patients to return within 4
to 6 weeks for debriefing by our nurses and collection of an
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abbreviated “report card” listing risk factors, complica-
tions, treatment goals, and key messages on self-care.
8. According to the recommendations, the nurses then
triaged patients to different care settings based on their
risk profiles eg, hospital-based clinics for those with
complications but stable control, community-based
clinics for those without complications and stable
control or specialist diabetes clinics for difficult-to-
treat patients with support from the nurse-led Diabetes
Center. Before discharge to the community, patients
were reminded of their rights and roles, techniques in
self-blood glucose monitoring and interpretation, and
the scheduled follow-up plan.
Hong Kong Diabetes Risk Equations
Although our Diabetes Registry was established as a
quality improvement program, we made use of the
universal health care system, which provides more than
95% of chronic care to patients in Hong Kong, to
research into this prospective cohort. In Hong Kong, all
patients attending public-funded clinics pay a nominal
fee for consultations, evaluations, and medications.
From 1996, all critical clinical information including
hospital discharges, outpatient clinic visits, procedures,
and medications dispensed on site were gradually
computerized by the Hong Kong Hospital Authority
Clinical Management System (CMS). Using the unique
Hong Kong Identity Card number, which is compulsory
for all citizens, we were able to identify and censor
clinical outcomes and use our comprehensive dataset to
establish risk equations with 70% to 95% prediction
accuracy or area under the receiver’s operating charac-
teristic curve.
Using this registry, which at the time of writing has
accrued 2616 clinical events in 9588 Chinese type 2
diabetic patients with a follow up duration of 6 years,
we have made important observations regarding the
phenotypic heterogeneity and impacts of treatments on
clinical outcomes. In this database, which exceeds
10,000 patients, only 3.7% had type 1 diabetes and
the rest had type 2 diabetes. The mean age of the type 2
diabetic patients was 57.4 years, with a median 5 years
of disease duration at the time of enrolment. The annual
event rate (cardiovascular disease, end-stage renal
disease [ESRD], cancer, and death) of this registry
was 43.0 per 1000 person years, depending on the
Fig. 1 Plan for using a team of
doctors, nurses, and clerks to
establish a diabetes registry for
quality assurance and risk strat-
ification to facilitate subsequent
triage of patients to different
clinic settings at the Prince of
Wales Hospital of the Chinese
University of Hong Kong since
1995
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patients’ risk profile. In contrast to whites in whom Coronary
Heart Disease (CHD) is the main cause of death, 20% of our
type 2 diabetic patients died with cancer (mainly liver,
colorectal, renal, and respiratory tract), 20% with coronary
heart disease (CHD) or heart failure, 11% with stroke, and
11% with respiratory disease [5, 6].
Diabetic Kidney Disease
Table 1 summarizes the predictors for each of these
clinical outcomes, including all-cause death with albu-
minuria and estimated glomerular filtration rate (eGFR),
as the common risk factors for all endpoints. In
agreement with other surveys [7, 8], 16.2% of our
diabetic patients had macroalbuminuria and 25% had
microalbuminuria, which were strongly predictive of
cardiorenal events and all-cause mortality [9]. During
the 6-year follow-up period, 19.1% of our patients
developed diabetic kidney disease (DKD), defined as
eGFR <60 mL/min/1.73m2. With the onset of DKD,
these patients had further increase in cardiovascular risk
due to retention of cytokines, heightened inflammatory
responses, abnormal calcium-phosphate metabolism, pro-
Table 1 A summary of predictors for multiple clinical endpoints identified by the Hong Kong Diabetes Registry
CHD Heart
failure










[9, 13, 39, 40, 46–50, 59,
60, 67]





Age √ √ √ √ √
Male gender √ √ √
Disease duration √ √
Ever smoked √ √
History of CHD √ √
PVD √
BMI √ √ √
Central obesity √
Metabolic syndrome √
HbA1c √ √ √ √ √
Blood pressure √ √ √




eGFR √ √ √
ACR √ √ √ √ √ √ √
White blood cell √ √
Blood Haemoglobin √ √
Blood
Hematocrit √ √ √
Erectile dysfunction √




History of cancer √







Genetic factors √ √ √ √ √
ACR—albumin/creatinine ratio; BMI—body mass index; CHD—coronary heart disease; eGFR—estimated glomerular filtration rate; HbA1c—
glycated hemoglobin; LDL-C—low-density lipoprotein cholesterol; HDL-C—high-density lipoprotein cholesterol; RAS—renin angiotensin
system; PVD—peripheral vascular disease.
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pensity for vascular calcification, and anemia [10].
Compared to an annual event rate of 2% to 3% in those
with eGFR >60 mL/min/1.73 m2, patients with DKD had
an annual event rate of 5% to 10% [11].
The importance of DKD in East Asian populations is
evidenced by 40% to 55% of patients on dialysis in these
countries having diabetes, compared to less than 30% in
Western countries, such as Australia [12]. In a multinational
study, Asian patients had higher prevalence of nephropathy
than their white counterparts. This might be in part due to
insufficient use of renoprotective drugs with only 20% of
Asian patients in this global survey receiving renin-
angiotensin system (RAS) blockers compared to 30% in
the white population [7]. In our registry, 25.1% of patients
were treated with angiotensin-converting enzyme inhibitors
(ACEI) or angiotensin II receptor blockers (ARB) at
enrollment. After enrollment, 32.6% were started on these
drugs, giving a total of 57.6% [9].
In addition to the possibility of delayed diagnosis or
suboptimal care, chronic low grade infection such as
hepatitis B virus (HBV) is present in 10% of the Chinese
population and may play a causal role in glomerulonephri-
tis. Using this prospective database, we have reported the
fourfold increased risk of ESRD in HBV carriers compared
to non-HBV carriers, after adjusting for other confounders
[13]. In support of these findings, Chinese type 2 diabetic
patients with nephropathy had activation of proinflamma-
tory cytokines and signaling pathways compared to those
without nephropathy [14, 15].
Despite the grave prognosis of patients with DKD, by
using a doctor–nurse or doctor–pharmacist team to imple-
ment a structured care protocol with defined procedures and
treatment targets, we were able to show dramatic benefits in
increasing the likelihood of achieving multiple treatment
goals, which translated to a 50% risk reduction in all
event rates after 2 years [16, 17•] (16). These results are
not dissimilar to that in the Steno-2 Study [18]. In
Taiwan, in a cohort of 1290 Chinese type 2 diabetic
patients with normoalbuminuria followed up for
3.5 years, 4.1% of the cohort attained three or more
treatment goals (HbA1c <7%, systolic BP <130 mm Hg,
diastolic BP <80 mm Hg, LDL-C <100 mg/dL; trigly-
cerides <150 mg/dL, and HDL-C >40 mg/dL or 50 mg/
dL in women) with 2% incidence of new onset of
microalbuminuria. This was compared to 8% in those
with one or two treatment goals (73%) and 10% in those
who did not attain any treatment goal (23%) [19].
Diabetes, Lipids, and Cancer
Since establishing the registry, the causes of death have
changed from the causes most often seen in the previous
two decades. From as early as the 1970s, the World Health
Organization Multicentre Vascular Disease in Diabetes
Survey demonstrated the propensity of Asian populations
to develop stroke and end-stage renal disease (ESRD)
whereas whites were more likely to develop CHD [20].
These inter-ethnic differences have also been confirmed in
the Asia Pacific Cohort Collaborative Study Group [21] and
randomized controlled trials such as Action in Diabetes and
Vascular Disease (ADVANCE) [22]. In the 1990s, stroke
and ESRD were the leading causes of death in our Chinese
diabetic patients [23]. In early 2000, with better control of
BP and access to dialysis, deaths due to stroke and ESRD
fell, whereas those due to CHD started to increase. With the
wider usage of lipid-lowering drugs and coronary inter-
ventions, the reduced mortality from cardiovascular diseases
has resulted, at least in part, in cancer becoming a more likely
cause of death in our type 2 diabetic patients [6].
Compared to the Hong Kong Cancer Registry, our
diabetic patients had 30% increased risk of all-site cancers
in all age groups in both men and women [6]. These
findings are in agreement with most meta-analysis on risk
association of cancer with diabetes [24]. Using the spline
analysis, we observed novel non-linear relationships
between cancer risk and lipid parameters. Both low and
high LDL-C levels were associated with increased cancer
risk with an optimal level of 3.28 mmol/L [25], whereas
patients with triglyceride level <1.7 mmol/L also had high
cancer risk. However, these risk associations were markedly
attenuated in patients treated with statins [26]. In addition,
there were interactive effects between low LDL-C and
albuminuria on cancer risk, which were attenuated by statin
use. In non-statin users, high white blood cell (WBC) count
(ie, ≥8.2×109 counts/L) was associated with increased
cancer risk, which was attenuated by RAS blockers [27].
The benefits of statins and RAS blockers on cancer risk
suggest that activation of the 3-hydroxy-3-methylgutaryl-
coenzyme A (HMG-CoA) reductase and RAS pathways
may play pivotal roles in carcinogenesis. These pharmaco-
epidemiologic findings were corroborated in a uni-
nephrectomized rat model that developed proteinuria,
hyperglycemia, dyslipidemia, renal dysfunction, and renal
cancer in a sequential manner. These changes were
accompanied by activation of the RAS, HMG-CoA
reductase, insulin-like growth factor 1 (IGF1), and Akt
pathways, all of which were attenuated by treatment with
angiotensin-converting enzyme inhibitors [28].
Glycemic Control and Cancer Risk
Recently, a series of observational studies has raised
concerns regarding the effects of blood glucose lowering
drugs, notably insulin analogue, on cancer risk in diabetic
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patients [29]. Insulin resistance and hyperinsulinemia
leading to dysregulation in IGF1 and steroid pathways are
often proposed as factors linking diabetes, obesity, and
cancer [30]. However, as early as 1956, Warburg [31]
reported that cancer cells thrived better in anaerobic
conditions by using glycolysis rather than tricarboxylic
acid (TCA) cycle to obtain energy for cell growth and (de)
differentiation. Using our diabetes registry, we were the
first to report the near linear relationship between cancer
risk and HbA1c level, with a threshold value of 6% to
6.5%. For every 1% increase in HbA1c, there was an 18%
increased risk of cancer after adjustment for covariates and
drug use during treatment. Furthermore, using a cohort
study design, we observed 52% risk reduction in cancer
incidence among insulin users compared to non-users after
adjustment for covariates, drug use during follow-up, and
propensity score for likelihood of insulin use [32]. In a
recent meta-analysis of randomized controlled trials
comparing intensive blood glucose lowering versus
standard treatment, for a 0.3% to 0.8% difference in
HbA1c, there was a non-significant 9% risk reduction in
cancer risk in the intensive-treatment group. Therefore,
findings from these published interventional studies
corroborate with our observational findings in these
cohort studies (0.55% increase in HbA1c and 9%
increased cancer risk) [33].
With better control of risk factors and aggressive
management of cardio-renal complications, there are now
more opportunities for cancer to develop, with an annual
incidence of approximately 1% in our registry. Although
results from the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study have raised concerns regarding
the risk-benefit ratio of intensive blood glucose lowering to
HbA1c <6.5% [34], our results suggest that the effects of
intensive glycemic control need to be systematically tested,
with cancer included as a primary clinical endpoint. Given
the earlier age of onset of disease and high risk of exposure
to carcinogens, such as chronic viral infections, tobacco,
and environmental toxins in Asia, early diagnosis and
intensive risk factor management could lead to major
benefits on multiple endpoints [35•].
Effectiveness of Drugs on Clinical Outcomes in Real
Settings
In Hong Kong, all medications are dispensed on site in the
public health care setting. All dispensing data are comput-
erized, which allows us to examine the effects of
medications on clinical outcomes in a real-life setting. In
this prospective cohort, 31% of patients were achieving two
or more treatment goals (HbA1c <7%, BP <130/80 mm Hg,
LDL-C <2.6 mmol/L), 41% were achieving one goal, and
28% were not achieving any goal at enrollment. After
6 years of follow-up, the former two groups had 40% and
20% risk reduction, respectively, in incident CHD com-
pared to those who did not attain any goal [36]. These
findings mirrored those reported in the randomized Steno
two study, which demonstrated the marked benefits of
multifactorial treatment on micro- and macrovascular
complications in type 2 diabetic patients with hypertension
and microalbuminuria [18].
Similarly, we were able to confirm the benefits of
RAS blockers in reducing cardio-renal complications in
patients with all degrees of albuminuria especially those
with micro- and macroalbuminuria [9], reinforcing the
findings from previous large-scale, randomized controlled
trials [37, 38]. Apart from showing the attenuating effects
of statins on cancer risk, we also reported the effects of
statin use in reducing new onset of DKD by 60% [39]. In a
subgroup analysis, we demonstrated possible causal
effects of high LDL-C on albuminuria and of low HDL-
C on eGFR. In experimental studies, urinary loss of
protein can lead to over-production of low- molecular-
weight lipoproteins, which can cause inflammatory
changes in the renal interstitium [40]. Given the close
link between renal dysfunction and cardiovascular dis-
eases, there is a need to conduct large-scale, randomized
controlled trials to examine the effects of statins on
multiple endpoints, including cardio-renal and cancer
events in Asian populations.
In whites, there is irrefutable evidence supporting the
cardioprotective effects of statins in both primary and
secondary prevention trials, although similar data are
lacking in Asian populations. Using this prospective
database, we were able to confirm the higher risk of
cardiovascular disease in Chinese type 2 diabetic patients
with LDL-C >3 mmol/L as a threshold value, whereas
the risk relationship with HDL-C was linear and
negative. Treatment with statins was associated with a
40% risk reduction in new onset of CHD, irrespective of
baseline LDL-C level. Pending definitive evidence from
randomized controlled trials, these observational data
strongly advocate the use of these life-saving drugs in
Asian patients [41].
Yet despite the recommendation of aspirin use in
diabetic patients until recently, we have reported the
paradoxical increase in risk of CHD in patients treated
with aspirin for primary prevention [42]. The negative
effect of aspirin on cardioprotection has recently been
confirmed in randomized controlled trials [43, 44] and
meta-analysis [45]. Therefore, the diabetes registry serves
not only as an invaluable quality assurance tool, it also
allows us to evaluate the risks and benefits of drugs on
clinical outcomes in a real setting and to make novel
observations for further testing.
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Genotype–Phenotype Interactions
When we set up this diabetes registry, we also sought
written informed consent from our enrolled patients to
donate their serum and DNA to establish a biobank for
study of genotype–phenotype correlations in Chinese
diabetic patients. Here, the familial clustering of diabetic
nephropathy strongly suggests the importance of genetic
predisposition for diabetic complications. In a subgroup
analysis, we reported the independent predictive roles of
genetic polymorphisms of aldose reductase [46], ACE [47],
lipases and apolipoproteins [48], and protein kinase C [49]
on development of cardio-renal endpoints, after controlling
for covariates and use of RAS blockers. Using a panel of
single nucleotide polymorphisms (SNPs) implicated in
cardiovascular diseases encoding stress responses, obesity,
lipid metabolism, BP control, and oxidative defenses, we
applied structural equation modeling to quantify the
complex phenotype–genotype interactions that explained
30% to 80% of variance of renal function [50]. Using
cardiovascular diseases as outcome measures, we further
observed the independent and additive effects of SNPs
implicated in oxidative stress, thrombosis, endothelial
dysfunction, and cytokines on cardiovascular diseases after
adjustment for conventional risk factors [51, 52]. Because
most of these genetic markers cannot be reflected by
intermediate phenotypes such as BP or lipids, these genetic
markers may be used to identify and subsequently refer
subjects with a high risk for diabetic complications for
intensive treatment.
Multidisciplinary Care through Communication
and Collaboration
During the early stage of the quality assurance and improve-
ment program and in collaboration with a group of primary care
doctors, we pioneered a shared-care program using structured
referral forms and follow-up procedures in primary and hospital
clinic settings. By setting up bi-weekly complication screening
sessions, we were able to re-engineer our clinic operation,
systematically screen patients for risk stratification, triage them
to appropriate care models, and reduce long waiting lists for
new referrals [53].
By using a doctor–nurse team to deliver a structured care
protocol, we have been able to reduce mortality and all-
event rates by 50% to 70% in diabetic patients with
multiple risk factors and renal dysfunction [17•]. In 2007,
we combined the concepts of risk stratification and
structured care to establish a web-based Joint Asia Diabetes
Evaluation (JADE) program. This state of the art electronic
portal consists of templates for data collection during
annual comprehensive assessment and follow-up visits, a
validated risk engine, care protocols guided by risk profiles,
decision support, and matrixes showing key performance
indexes (eg, percentage of patients on treatment goals or
with poor risk factor control). The portal enables doctors to
establish their own diabetes registry and provides summary
reports with charts/diagrams to illustrate trends of risk
factors control (HbA1c, BP, LDL-C, body weight) and
practice tips to both care providers and patients. With
patients’ written informed consent, this anonymous data-
base will contribute to a regional prospective cohort to
validate the various Hong Kong Risk Equations in a larger
Asian population, set benchmarks for quality of care, and
promote cooperative learning to improve care standards
[54•, 55•].
Conclusions
By late 1990s, these complication screening services have
become standard practices in all diabetes centers in public
hospitals. In 2008, the Hong Kong government identified
diabetes and hypertension as priority health care areas and
invested heavily in primary care clinics to implement
similar risk stratification and diabetes management and
education programs to improve chronic care in the
community.
From a research perspective, ongoing data collection and
analysis of the registry has provided new insights into
differences and similarities in presentation, disease progres-
sion, and outcomes between Chinese (Asian) and white
populations. Results from our pharmaco-epidemiologic
analysis have validated international recommendations
often based on data collected from white populations.
However, we have also demonstrated the phenotypic
heterogeneity, predisposition to DKD, and emerging
importance of cancer in Asian population that will require
novel strategies to reduce these disease burdens. These
epidemiologic results will provide important data for study
design to ensure that the results are clinically meaningful
and applicable to the Asian populations.
Finally, in this post–genome-wide association and
sequencing era, well-designed cohort studies with detailed
phenotypes have become invaluable resources to enable
researchers to make novel and clinically meaningful
discoveries. By setting up a diabetes registry accompanied
by a biobank, clinician scientists are uniquely placed to
contribute to the understanding of this complex disease
using a genomic approach, through risk prediction, risk
stratification, and personalized care in order to maximize
benefits and minimize harm.
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